Clinical Trial Update: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of Sofpironium bromide for axillary hyperhidrosis has completed and results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axillary Hyperhidrosis

Drugs mentioned

• Sofpironium bromide (Sofpironium bromide)

Snippet

Sponsor: Botanix Pharmaceuticals | Conditions: Axillary Hyperhidrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-05-21